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With majority of ischemic strokes attributable to atherothrombosis and many being predictable after transient ischemic attacks
(TIA), the role of early secondary prevention with antiplatelet agents is under renewed investigation. Prior major clinical trials
of various secondary stroke prevention regimens pointed to a greater eﬃcacy of dual antiplatelet agents if initiated early from
symptom onset. This paper examines data and rationale behind dual antiplatelet regimens across the completed clinical trials.
The safety of dual antiplatelets approach is of concern, but it could be outweighed, at least in early management, by a greater
reduction inrecurrence ofischemicevents sincethisriskis“frontloaded” afterminorstrokeorTIA.Aspirin monotherapy,though
considered standard of care, is compared to aspirin-extended release dipiridamole and its combination with clopidogrel in early-
phase completed and eﬃcacy-phase ongoing clinical trials.
1.Introduction
Stroke is increasingly recognized as a devastating disease,
causing signiﬁcant mortality and long-term disability world-
wide. Each year in the United States, approximately 795.000
people experience a new or recurrent stroke, at least 600.000
of these are ﬁrst attacks, and 185.000 are recurrent events.
Mortality data from 2006 indicate that stroke accounted for
approximately 1 of every 18 deaths in the United States [1].
The incidence of transient ischemic attacks (TIAs) in the
United States has been estimated to be 200.000 to 500.000
per year [1]. Recurrence risk after TIA or ischemic stroke
ranges from 5% to 20% per year [2–5]. The highest risk is
within the ﬁrst few days after the initial event [6, 7]. Risk
of subsequent vascular events other than strokes—unstable
angina, myocardial infarction (MI), ventricular arrhythmias,
or deaths due to heart failure—is also elevated after TIA
[8, 9].
Up to 90% of all strokes are ischemic in nature, with
the remaining 10% resulting from intracerebral hemorrhage
or subarachnoid hemorrhage [1]. The majority of ischemic
strokes are of arterial origin such as atherothrombosis—
ad i ﬀuse, generalized and progressive polyvascular disease.
Atherothrombosis plays a key role in most of acute ischemic
strokes,unstableangina,acuteMI,suddencardiacdeath,and
peripheral arterial disease (PAD).
With respect to the brain, atherosclerotic plaques may
aﬀecttheintracranialandextracranialarteries.SimilartoMI,
these plaques can rupture, causing lipid and collagen expo-
sure, platelet aggregation, and clot formation. A platelet-rich
thrombus on the surface of a ruptured or eroded plaque
may result in a partial or complete obstruction of blood2 Stroke Research and Treatment
ﬂow and artery-to-artery embolization [10]. The interaction
of platelets with atherosclerotic lesion is central to this
pathologicalprocess[10,11]. Platelettethering and adhesion
tothearterialwallaswellasaggregationareachievedthrough
multiple high-aﬃnity interactions between platelet mem-
brane receptors (integrins) and ligands within the exposed
subendothelium [11]. Recent evidence supports the fact
that thrombosis and inﬂammation are interrelated (platelets
are involved in inﬂammation and, similarly, leukocytes are
involvedin hemostasis). The platelet, which was once viewed
as a bystander in hemostasis, is now recognized as a key
mediator of thrombosis as well as inﬂammation.
Antithrombotic drugs block platelet aggregation and
activation at various points in the thrombotic cascade
and include aspirin, thienopyridines (clopidogrel and its
predecessor ticlopidine), intravenous GP IIb/IIIa inhibitors,
which block the ﬁnal common pathway of platelet activation
andaggregation, unfractionated heparin and low-molecular-
weight heparin, and direct thrombin inhibitors. Currently,
available antiplatelet drugs (aspirin, dipyridamole, clopi-
dogrel, ticlopidine, prasugrel abciximab, eptiﬁbatide, and
tiroﬁban) act on speciﬁc targets to inhibit platelet activation
and aggregation [12]. Clopidogrel eﬀectively inhibits ADP-
induced platelet activation and aggregation by selectively
and irreversibly blocking the P2Y12 receptor on the platelet
membrane. Aspirin works by irreversibly acetylating the
cyclooxygenase (COX-1) enzyme, thus suppressing the pro-
duction of thromboxane A2 (TXA2) and inhibiting platelet
activation and aggregation [12].
The antithrombotic eﬀect of dipyridamole is through
phosphodiesterase inhibition and depends on stimulation
of platelet cyclic A.M.P. by circulating prostacyclin in the
bloodstream. Dipyridamole acts on the vascular endothe-
lium by increasing endothelial production of nitric oxide,
and it may facilitate aspirin’s platelet inhibition by parallel
mechanisms thatinhibit theproliferation ofvascular smooth
muscle and vasoconstriction. This enhanced vasodilatation
has been shown to decrease endothelial inﬂammation by
inhibiting endothelial leukocyte adhesion [12].
Elucidation of the multiple mechanisms involved in
platelet thrombus formation provides opportunities for
selectively inhibiting the pathways most relevant to the
pathophysiology ofatherothrombosis [12]. Alongwith other
secondary prevention measures, antiplatelet therapy remains
a key component of atherothrombotic event prevention.
Numeroustrials andmeta-analyses haveconﬁrmed theeﬀect
of an antiplatelet therapy to reduce the risk of vascular
events recurrence in patients with prior stroke or TIA [13–
15]. Nevertheless, controversies exist and the debate is now
focused on the optimal antiplatelet regimen. The majority of
research in secondary stroke prevention supports the clinical
value of aspirin. Whether aspirin remains the best available
antiplatelet drug for stroke prevention and if it should be
used alone or in combination with another antiplatelet agent
more eﬀective than aspirin monotherapy are still a matter of
debate.
Herein, we review the current available data on
antiplatelet therapies in stroke prevention and the rationale
behind the use of dual antiplatelet regimens.
2.AntiplateletTherapyin
SecondaryStrokePrevention
2.1. Aspirin. For secondary prevention of vascular events
(stroke, MI, and vascular death), the beneﬁts of aspirin are
well established. This has been summarized by data from the
AntithromboticTrialists’collaboration[13].The bottomline
is that aspirin 50–325mg/day doses reduce the odds of such
an event in patients at an increased risk of a cardiovascular
event[13].Ameta-analysisoftwostudieswithatotalof2980
patientswithahistoryofischemicstrokeorTIArevealedthat
aspirin decreasestherisk ofrecurrent strokeby20–30%[16].
In acute ischemic stroke, aspirin also has a modest eﬀect.
The Chinese Acute Stroke Trial (CAST) and International
Stroke Trial (IST) studies found that acute treatment with
aspirin after ischemic stroke reduced the risk for recurrent
ischemic stroke by 30% (relative risk reduction) with a small
increase ofintracerebral hemorrhage (25% relative and 0.2%
absolute increase) over 2–4 weeks of treatment [17–19]. The
overall beneﬁt of acute treatment with aspirin was present
in those with and without atrial ﬁbrillation and with and
without a lacunar syndrome [19]. Thus, aspirin has become
the standard of care in the acute treatment of patients with
acute stroke. Aspirin is also considered standard therapy
in TIA, with clopidogrel and aspirin plus dipyridamole
acceptable alternatives [12, 20].
The antiplatelet eﬀect of aspirin is not absolute in all
patients, and some patients experience thromboembolic
events despite aspirin. This observation has represented
the basis for the establishmento ft h ec o n c e p to f“ a s p i r i n
resistance,” which can be clinical or laboratory resistance.
Possible causes of aspirin resistance include poor com-
pliance, inadequate dose, drug interactions, genetic poly-
morphisms of cyclooxygenase-1, increased platelet turnover,
and upregulation of nonplatelet pathways of thromboxane
production. Moreover, no single platelet activation pathway
is responsible for all thrombotic complications, and a single
treatment strategy directed against a speciﬁc receptor/target
cannot overcome all thrombotic complications. However,
aspirin-resistant patients,accordingtothecurrentlyavailable
laboratory tests, present a higher occurrence of cardiovas-
cular events, when compared to nonresistant ones. There
is currently no standardized approach to the diagnosis and
no proven eﬀective treatment for aspirin resistance. Further
studies, with standardization of the laboratory tests used
and the clinical outcomes as well as larger sample sizes, will
contributeto a betterunderstanding of the aspirin-resistance
phenomenon [21].
2.2. Aspirin plus Extended Release (ER) Dipyridamole. The
European Stroke Prevention Study 2 (ESPS-2) demonstrated
a signiﬁcant reduced risk (37%, P<. 001) of recurrent
stroke in 6600 patients with recent ischemic stroke or TIA
who were treated with the combination of aspirin plus
extended release (ER) dipyridamole compared to aspirin
and dipyridamole monotherapy (18% and 16%, resp.) [22].
The European/Australian Stroke Prevention in Reversible
Ischaemia Trial (ESPRIT) tested the eﬃcacy of aspirin (30–
325mg/day) with or without ER-dipyridamole in patientsStroke Research and Treatment 3
with stroke or TIA within 6 months from symptom onset.
The combinationtherapy resulted ina relative risk reduction
(20%, hazard ratio 0.80, 95% CI 0.66–0.98) of all vascular
events compared to aspirin monotherapy [23]. However,
neitherofthesetrials evaluatedtheacuteperiodafterastroke
or TIA (median time to enrollment was >1 month), so safety
and eﬃcacy during this time period is unknown.
Recently, the EARLY trial showed that early initiation of
aspirinplusER-dipyridamole within24hoursofstrokeonset
is likely to be safe and eﬀective in terms of good functional
outcome compared to initiation after 7 days (mRS 0–2; OR
1.37, 95% CI 0.86–2.18, P = .19) [25]. These ﬁndings
suggest feasibility of testing aspirin plus ER-dipyridamole
in an eﬃcacy clinical trial for acute stroke treatment and
secondary prevention.
The Prevention Regimen for Eﬀectively Avoiding Second
Strokes (PROFESSs) trial was the largest secondary stroke
prevention study completed to date. It compared ER-
dipyridamole plus aspirin versus clopidogrel [24]. A total
of 20332 patients were followed for a mean of 2.5 years.
Recurrent stroke occurred in 916 patients (9.0%) receiving
ER-dipyridamole plus aspirin and in 898 patients (8.8%)
receiving clopidogrel(hazard ratio,1.01;95%CI,0.92–1.11).
No statistical diﬀerences were found in either arm for the
primary outcome of fatal or nonfatal stroke or prespeciﬁed
secondary endpoints. ER-dipyridamole plus aspirin also was
associated with an increase in major hemorrhagic events
but no statistically signiﬁcant increase in combined rates of
stroke recurrence or hemorrhage. The fact that both agents
performedonparinPROFESStrialcouldbeviewedasifthey
oﬀer no advantages and may lead some to consider aspirin
as the choice for secondary prevention over these agents.
It is important to note that the comparison to aspirin was
not the goal of PROFESS, and these results should only be
used to compare clopidogrel and aspirin-ER-dipiridamole
regimens.
2.3. Clopidogrel Monotherapy. In the Antiplatelet Trialists’
Collaboration, clopidogrel produced a 10% relative reduc-
tion in the incidence of seriousv a s c u l a re v e n t si np a t i e n t s
with a history of MI, stroke, or PAD compared with aspirin
(P = .03) [13]. In the Clopidogrel versus Aspirin in Patients
at Risk of Ischemic Events (CAPRIEs) trial, clopidogrel
75mg/dayreducedlong-termrisk ofthecomposite endpoint
of vascular death, stroke, MI, or rehospitalization for an
ischemic event or bleeding by 8.7% (relative risk reduction,
P = .047) compared to aspirin 325mg/day in patients with
symptomatic atherothrombotic disease (stroke, MI, or PAD)
[26]. There was no increased risk of hemorrhage or other
major side eﬀects observed. Although clopidogrel appears to
be particularly beneﬁcial in a subgroup of patients with PAD
[26], diabetes[27],or a history of revascularization/ischemic
events before enrollment [28, 29], the results should be
interpreted with caution as they were obtained from post-
hoc [27–29] and predeﬁned secondary analysis [26]. Partic-
ularly, in patients with a history of ischemic stroke or MI,
clopidogrel was superior to aspirin in reducing the risk of
an ischemic stroke, MI, or vascular death [29]. Of note, the
CAPRIE trial was not designed to evaluate clopidogrel as an
acute therapy, and no trial has yet evaluated the eﬃcacy of
clopidogrel after TIA.
Similar to aspirin, “resistance” to clopidogrel has been
reported [30]althoughthereiscurrentlynoconsensus which
assay should be standard to establish resistance with limited
directclinicalcorrelationshown sofar. Ahigher loadingdose
of 600mg clopidogrel may produce platelet inhibition faster
(i.e., at 3-4 hours) than loading with 300mg. Furthermore,
600mg dose is more likely to be eﬀective in those with
clopidogrel “resistance” [31].
2.4. Aspirin plus Clopidogrel in Other Vascular Syndromes.
The Clopidogrel in Unstable Angina to Prevent Recurrent
Events (CUREs) trial of patients with acute coronary syn-
dromes demonstrated that clopidogrel 75mg/day after a
loading dose of 300mg plus aspirin reduced the risk of
stroke, MI, and vascular death by 20%, and the eﬀect was
clear in the ﬁrst 10 days compared to aspirin alone [32, 33].
There was a small increase in risk of major hemorrhage but
no diﬀerence in life-threatening hemorrhage. Similar results
of combined antiplatelet therapy were seen in patients with
ST-segment elevation MI in the Clopidogrel and Metoprolol
in Myocardial Infarction Trial (COMMIT) and the Addition
of Clopidogrel to Aspirin and Fibrinolytic Therapy for
Myocardial Infarction with ST-Segment Elevation (CLAR-
ITY) trial [34, 35].
2.5. Aspirin Plus Clopidogrel for Long-Term Secondary Stroke
Prevention. In the Management of Atherothrombosis with
Clopidogrelin High-risk (MATCH)patients with recent TIA
or ischemic stroke trial, addition of aspirin to clopidogrel
showed no beneﬁt in reduction of major vascular events
in high-risk patients with prior stroke or TIA (relative risk
reduction 6.4%, P = .244) due to a higher absolute risk
(1.3%, P<. 0001) of life-threatening bleeding on dual
antiplatelets compared to clopidogrel monotherapy [36]. In
a subgroup analysis, however, there was a trend toward a
greater beneﬁt in those treated sooner after the qualifying
stroke or TIA, with a decrease of the relative risk (17%) in
those treated within 7 days.
Against the background of MATCH, the Clopidogrel
for High Atherothrombosis Risk and Ischemic Stabiliza-
tion Management and Avoidance (CHARISMA) trial was
designedtodeterminewhetherdualantiplatelettherapywith
clopidogrel and aspirin is superior to aspirin alone in terms
of prevention in high-risk asymptomatic patients (with ≥3
risk factors) or symptomatic patients with documented
cerebrovascular disease, coronary artery disease, or PAD
[37]. In this trial, 15603 patients were randomized to receive
clopidogrel (75mg/day) or placebo, in combination with
low-dose aspirin (75–162mg), for a median of 28 months.
Similar to MATCH, the study showed that the combination
of the antiplatelet agents clopidogrel and aspirin was not
associated with a statistically signiﬁcant reduction in the risk
of heart attack, stroke, or cardiovascular death compared
to placebo and aspirin alone (6.8% versus 7.3%; relative
risk 0.93; P = .22). There was an insigniﬁcant trend
toward an increased incidence of severe bleeding among
clopidogrel plus aspirin group (1.7% versus 1.3%; relative4 Stroke Research and Treatment
risk 1.25%; P = .09) but no diﬀerence in the risk of primary
intracranial hemorrhage (0.3% in both groups; relative risk
0.96; P = .89). However, also similar to MATCH, there
was a greater beneﬁt in patients treated sooner after clinical
qualifying event (including stroke and TIA) [38]. Findings
for the primary composite endpoint diﬀered in the asymp-
tomatic and symptomatic patients subgroup. In patients
with established atherothrombotic disease, the CHARISMA
ﬁndings demonstrated that clopidogrelin addition toaspirin
reduced the relative risk of MI, stroke, or cardiovascular
death by a statistically signiﬁcant 12.5 percent (P = .046)
compared to patients receiving placebo and aspirin. These
patients accounted for nearly 80 percent (n = 12153)
of the total CHARISMA study population. Patients with
multiple risk factors but no clearly established vascular
disease did not beneﬁt from the addition of clopidogrel
to aspirin (20 percent relative risk increase, P = .22).
These patients represented approximately 20 percent (n =
3284) of the overall study population. In this subgroup,
severe bleeding occurred in 2% of clopidogrel recipients
compared with 1.2% in the placebo groups (P = .07)
[38].
In the Atrial Fibrillation Clopidogrel Trial with Irbesar-
tan for Prevention of Vascular Events (ACTIVE-W)—with
theaimtoassess thenoninferiorityofdualantiplatelettooral
anticoagulation therapy for prevention of vascular events—
patients with atrial ﬁbrillation at high-risk factor for stroke
were randomly allocated to receive oral anticoagulation
therapy (target international normalised ratio of2.0-3.0; n =
3371)orclopidogrel(75mgperday)plusaspirin(75–100mg
per day; n = 3335)). The study was stopped early because
of clear evidence of superiority of oral anticoagulation
therapy. There were 165 primary events in patients on oral
anticoagulationtherapy(annualrisk3.93%)and234inthose
on clopidogrel plus aspirin (annual risk 5.60%; relative risk
1.44 (1.18–1.76; P = .0003). Rates of major haemorrhages
were similar in the two groups (2.2% versus 2.4% per year,
P = .53); however, among participants in ACTIVE W
who were not receiving warfarin at entry, the risk of major
bleedingwassubstantiallylowerwithclopidogrelplusaspirin
than with warfarin [39].
Subsequently, results of the recent Atrial Fibrillation
Clopidogrel Trial with Irbesartan for Prevention of Vascular
Events(ACTIVE-A)study showed that in patients who could
not take oral anticoagulants and at high risk of developing
vascular events the combination of clopidogrel and aspirin
reducedmajorvascular events,particularly stroke,compared
with placebo [40]. In this study, 7554 patients with atrial
ﬁbrillation were randomized to receive either clopidogrel
75mg or placebo in addition to aspirin daily. After a median
followup of 3.6 years, a signiﬁcant (11%) reduction in
vascular events especially stroke (28%, P<. 00002) was
observed in those receiving aspirin plus clopidogrel as com-
pared with placebo, contributed primarily by a reduction in
the incidence of disabling strokes. These beneﬁts, however,
come at a high cost of bleeding complications; a 58% higher
incidence (P<. 0001) of major and severe bleeding was
observedin thosereceiving clopidogrelplusaspirin, aﬀecting
predominantly the gastrointestinal tract, possibly cancelling
the beneﬁt from reduction in vascular events. ACTIVE-A
now adds to our understanding of the role of intensive
antiplatelet therapy to prevent stroke in selected patients
with atrial ﬁbrillation. Major clinical implications arising
from ACTIVE-A trial for patients with atrial ﬁbrillation
who are at moderate-to-high risk for stroke and for whom
oral anticoagulants are suitable should be considered for
anticoagulation therapy to maximize the prevention of
thromboembolismwithanacceptableriskofmajorbleeding.
Therefore, in patients with atrial ﬁbrillation who are at
moderate-to-highriskforstrokeandanticoagulationtherapy
is contraindicated or those who are at lower risk for stroke,
combination therapy with clopidogrel and aspirin will most
likely provide a net clinical beneﬁt as compared with aspirin
alone [39, 40].
2.6. Aspirin plus Clopidogrel for Prevention of Stroke Pro-
gression and Early Recurrence. Recent results of the asymp-
tomatic embolisation for prediction of stroke in the Asymp-
tomatic Carotid Emboli Study (ACES) suggest that the use
of TCD to detect embolic signals might help with risk
stratiﬁcation of patients with high-grade but asymptomatic
carotid stenosis [44]. This observational prospective study
sought to determine if detection of asymptomatic microem-
bolic signals (MESs) using TCD could help in predicting
the risk for subsequent stroke among patients with high-
grade (≥70%) asymptomatic stenosis who were as yet
asymptomatic. Among 467 patients, 77 (16.5%)had embolic
signals on TCD at baseline. During follow-up, there were 26
(33.8%) ipsilateral TIAs and six (7.8%) ipsilateral strokes.
The presence of MES at baseline was signiﬁcantly correlated
with risk for subsequent ipsilateral stroke and TIA (hazard
ratio, 2.54; 95% CI 1.20–5.30; P = .015). One potential
mechanism of how combined antiplatelet therapy could be
beneﬁcial in these patients has been demonstrated in the
Clopidogrel and Aspirin for the Reduction of Emboli in
Symptomatic carotid Stenosis (CARESS) and more recently
Clopidogrel plus Aspirin for Infarction Reduction in acute
stroke or transient ischaemic attack patients with large
artery stenosis and microembolic signals (CLAIR) trials [41,
43]. CARESS evaluated the impact of the combination of
clopidogrel and aspirin versus aspirin alone on presence of
silent MES in 107 patients with signiﬁcant internal carotid
artery stenosis. At 7 days, 44% on the combination and 73%
on aspirin alone had persistent MES (relative risk reduction
39.8%, P = .0046), suggestive of a reduction in ongoing
thromboembolism [41]. CLAIR enrolled patients with acute
ischemic stroke or TIA with symptomatic intracranial or
extracranial artery stenosis and in whom MESs were present
on TCD. Ninety-three patients (93%) with intracranial and
seven (7%) patients with extracranial stenosis were assigned
within 7 days of symptom onset either to clopidogrel
(300mg for the ﬁrst day, then 75mg daily) plus aspirin
(75–160mg daily) or aspirin alone (75–160mg daily) for
7 days, and the primary endpoint was the proportion of
patients who had MES on day 2. One-third of patients who
received dual antiplatelets and half of patients with aspirin
monotherapy had at least one MES (relative risk reduction
42.4%, 95% CI 4.6–65.2; P = .025) suggesting the signal ofStroke Research and Treatment 5
Table 1: Randomized clinical trials on aspirin plus dipyridamole after stroke or TIA.
Trial Population Antiplatelet regimen Endpoints Major ﬁndings
ESPS-2 [22]
6602 patients with
prior (<3m o n t h s )
TIA or ischemic
stroke
Aspirin 25mg twice daily
or ER-dipyridamole
200mg twice daily
oraspirin 25mg plus
ER-dipyridamole 200mg
twice daily or placebo
Stroke (fatal or nonfatal),
death, stroke and/or death
Signiﬁcantrisk reduction (37%,
P<. 001) in primary endpoint with
combination therapy
ESPRIT [23]
2603 patients with
prior (<6m o n t h s )
TIA or minor
ischemic stroke of
arterial origin
Aspirin 30–325mg/d plus
dipyridamole 200mg
twice daily or aspirin
30–325mg/d alone
Vascular death, nonfatal
stroke, nonfatalMI, or
major bleeding
complication
Signiﬁcantrelative risk reduction
(20%, hazard ratio 0.80, 95% CI
0.66–0.98) in the primary endpoint
with combination therapy
PROFESS [24]
20332 patients with
prior stroke (<3
months)
Aspirin 25mg plus
ER-dipyridamole 200mg
twice daily or clopidogrel
75mg/d alone
Stroke recurrence and
composite of stroke, MI,
or vascular death
The trial did not meet the
predeﬁned criteria for
noninferiority. Recurrent stroke:
9.0% ER-dipyridamole plus aspirin,
8.8% clopidogrel; hazard ratio 1.01,
95% CI 0.92–1.11. Composite
endpoint: 13.1% ER-dipyridamole
plus aspirin, 13.1% clopidogrel;
hazard ratio 0.99, 95% CI
0.92–1.07, P = .83
EARLY [25]
543 patients with
ischemic stroke
within 24 hours of
symptomonset
Aspirin 25mg plus
ER-dipyridamole 200mg
twice daily or aspirin
100mg/d alone for 7 days.
All patients were then
given aspirin plus
ER-dipyridamole for up
to 90 day
Functional neurological
status (mRS) at 90 days.
Vascular adverse events
(nonfatal stroke, TIA,
nonfatal MI, and major
bleeding complications)
and mortality within ﬁrst
90 days
No signiﬁcant diﬀerence between
the groups in good functional
outcome (mRS 0–2; OR 1.37, 95%
CI 0.86–2.18, P = .19). No
signiﬁcant diﬀerence between the
groups in composite endpoint
(hazard ratio 0.73, 95% CI
0.44–1.19, P = .20)
Legend: TIA: transient ischemic attack;ER: extended released; MI: myocardial infarction; CI: conﬁdence interval.
eﬃcacy of dual antiplatelet therapy in reducing the embolic
potential of symptomatic intracranial atherosclerotic disease
[43].
TheresultsoftheFastAssessment ofStrokeandTransient
Ischemic Attack to prevent Early Recurrence (FASTER)
pilot trial also pointed to an increased risk of intracranial
hemorrhage in patients treated with clopidogrel plus aspirin
[42]. In this trial, 390 patients were randomized to aspirin
(162mg loading dose plus 81mg/day) and clopidogrel
(300mg load and 75mg/day afterwards) or aspirin alone
w i t h i n2 4h o u r so fam i n o rs t r o k eo rT I A .A t9 0d a y s ,
the risk of stroke (ischemic or hemorrhagic) was 11% in
those treated with aspirin alone and 7% in those treated
with clopidogrel and aspirin, resulting in an insigniﬁcant
3.8% relative risk reduction (P = .19). However, those
patients who were treated with clopidogrel plus aspirin had
a small but signiﬁcantly higher rate (P = .0001) of both
symptomatic andasymptomatic hemorrhages. Ofnote,these
hemorrhages were included in the primary outcome and did
not overwhelm the beneﬁt (see Tables 1 and 2 for details).
Several trials testing the safety and eﬃcacy of combined
antiplatelet therapy in patients with acute ischemic stroke
and TIA are underway. The Aortic arch-Related Cerebral
Hazard (ARCH) trial compares the eﬃcacy of anticoagulant
therapy with that of aspirin plus clopidogrel in preventing
stroke in high-risk patients with aortic arch atheromas
[45]. The Secondary Prevention of Small Subcortical Strokes
(SPS3) study was designed to determine the safety and
eﬃcacy of combined antiplatelet therapy with aspirin plus
clopidogrel versus aspirin monotherapy in the prevention
of stroke, major vascular events among patients with small
subcortical strokes [45]. The COMbination of Clopidogrel
and Aspirin for Prevention of Early REcurrence in Acute
Atherothrombotic Stroke (COMPRESS) trial is comparing
the eﬃcacy of the combination therapy (clopidogrel plus
aspirin) versus aspirin alone to prevent any recurrent
ischemic lesion evidenced by neuroimaging as primary
outcome and the eﬃcacy in preventing all strokes, vascular
death, and all bleedings as secondary one [45].
At last, the Platelet-Oriented Inhibition in New TIA and
Minor Ischemic Stroke (POINT) trial investigates whether
clopidogrel 75mg/day after a loading dose of 600mg of
clopidogrelis eﬀectivein preventing major ischemic vascular
events (ischemic stroke, MI, and ischemic vascular death)
at 90 days when initiated within 12 hours of TIA or
minor ischemic stroke onset in patients receiving aspirin 50–
325mg/day [45].
3.ConclusionsandPerspectives
Oral antiplatelet agents are an integral component of
pharmacotherapy for the reduction of atherothombotic6 Stroke Research and Treatment
Table 2: Randomized clinical trials on aspirin plus clopidogrel at diﬀerent timing after stroke or TIA.
Trial Population Antiplatelet regimen Primary Endpoints Major ﬁndings
MATCH [36]
7599 high-risk patients
with prior (<3m o n t h s )
ischemic stroke or TIA
Aspirin 325mg/d plus
clopidogrel 75 mg/d
versus clopidogrel
75mg/d alone.
Ischemic stroke, MI,
vascular death
Nonsigniﬁcantrelative risk reduction (6.4%,
P = .244) in the primary endpoint in
aspirin/clopidogrel group. Increased risk for
major or life-threatening bleeding in
aspirin/ clopidogrel group (P<. 0001)
CHARISMA [37]
15603 patients with
established prior CVD
(<5y e a r s )o rm u l t i p l e
vascular risk factors
Clopidogrel 75mg/d
plus aspirin
75–162mg/d versus
aspirin 75–162mg/d
alone
MI, Stroke, or
vascular death
Nonsigniﬁcantrelative risk reduction (7%,
P = .22) in primary endpoint in
aspirin/clopidogrel group. Increased risk for
moderate bleeding in clopidogrel/aspirin
group (P<. 001)
ACTIVE-A [40]
7554 high-risk AF
patients, unsuitable for
vitamin K antagonists
Clopidogrel 75mg/d
plus aspirin 75–100
mg/d versus placebo
plus aspirin
75–100mg/d
Stroke, MI, systemic
embolism, vascular
death
Signiﬁcantreduction in major vascular
events especially stroke (28%, P<. 00002) in
the aspirin/clopidogrel group. Signiﬁcant
increased risk of major hemorrhage in
clopidogrel/aspirin group (58%, P<. 0001)
CARESS [41]
107 patients with TIA or
ischemic stroke (<3
months) due to carotid
artery stenosis and MES
on TCD
Clopidogrel 300 mg
load, then 75mg/d plus
aspirin 75mg/d versus
aspirin 75mg/d alone
Proportion of
patients with MES at
day 7, MES
frequency per hour
at days 2 and 7
Signiﬁcantrelative risk reduction in both
primary (39.8%, P = .0046) and secondary
(61.6%, P = .0005 and 61.4%, P = .0013,
resp.) endpoints in aspirin/clopidogrel
group
FASTER [42]
392 patients with TIA or
minor stroke within 24
hours of symptom onset
Clopidogrel 300mg
load, then 75mg/d plus
aspirin 81mg/d plus
simvastatin 40 mg/d
versus aspirin (±
simvastatin) alone
Any stroke (ischemic
or hemorrhagic)
within 90 days
Nonsigniﬁcantabsolute risk reduction
(3.8%, P = .19) in primary outcome among
patients with aspirin/clopidogrel.
Nonsigniﬁcantabsolute risk increase (1.0%,
P = .5) in rate of intracranial hemorrhage in
aspirin/clopidogrel group.
CLAIR [43]
100 patients with
symptomatic (TIA or
stroke within previous 7
days) intra- or
extracranial artery
stenosis and MES on
TCD
Clopidogrel 300mg
load, then 75mg/d plus
aspirin 75–160 mg/d
versus aspirin alone for
7d a y s
Proportion of
patients with MES at
day 2
Signiﬁcantrelative risk reduction in primary
endpoint (42.4%, P = .025) in
aspirin/clopidogrel group. 93 of 100 patients
had symptomatic intracranial stenosis in
either the intracranial internal carotid artery
or the middle cerebral artery
Legend: MI: myocardial infarction; TIA: transient ischemic attack; CVD: cerebrovascular disease; AF: atrial ﬁbrillation; MES: microembolic signals; TCD:
transcranial Doppler.
events in patients with stroke and TIA. They should be
considered early after a noncardioembolic TIA as part of a
comprehensive and proactive approach to secondary stroke
prevention as demonstrated in the EXPRESS trial [46].
However, their eﬃcacy remains limited as they lower
the risk modestly and do not eliminate it completely. To
achieve better eﬃcacy early after stroke or a TIA, a dual
antiplatelet regimen could still prove beneﬁcial, similar to
lessons from cardiology. Aspirin inhibits platelet aggregation
by inhibition of cyclooxygenase,whereas clopidogrelreduces
platelet activation via ADP receptor-dependent pathways.
Based on these diﬀerent modes of action, it is an attractive
concept that the combination of both drugs may have
additive eﬀects on platelet inhibition.
This potential advantage of a dual antiplatelet regimen
maybeparticularly usefulinTIA[46].Infact,TIArepresents
per se a unique, important type of cerebral ischemia
characterized by substantial instability. The pathophysiology
of TIA is analogous to that of acute coronary syndromes
(i.e., unstable angina and non-Q-wave MI) in which throm-
bosis and thrombolysis are acutely active and protracted
[47]. Similarly, cerebral ischemia that acutely recovers may
beamarkerforongoingthrombosis-thrombolysis, amenable
to acute antiplatelet therapy [47–49].
Aggressive, early antiplatelet therapy with combinations
of agents is highly eﬀective in acute coronary syndromes.
In the TIA scenario, comparable to unstable angina, acute
treatment with dualantiplatelet regimen ispotentially highly
consequential and has never yet been properly studied.
Diﬀerently from the long-term secondary stroke prevention
and considering the front loading of recurrent events in the
acute phase of stroke, the higher risk of bleeding in the acute
phasemaybeoutweighedbylowerratesofstrokeprogression
or recurrence.
Ifproveneﬃcacious,dualantiplatelettherapyintheearly
phase after brain ischemic events would present a treatment
optionfor thethousands ofpatientswith stroke ineligiblefor
revascularization therapies.Stroke Research and Treatment 7
In summary, accumulating evidence from randomized
clinical studies suggests that aspirin monotherapy, clopi-
dogrel monotherapy, and ER-DP monotherapy provide
comparable beneﬁt for the prevention of recurrent stroke
after stroke or TIA.
Dual antiplatelet therapy for long-term secondary stroke
prevention, especially with aspirin and clopidogrel, has not
beenshownasanetbeneﬁtversusaspirinalonewhileitcould
result in greater bleeding complications. Currently, the only
therapy that has been shown to be better than aspirin alone
for the prevention of recurrent stroke is the combination
of aspirin plus ER-DP.However, the risk of thrombosis is
extremely high in the acute period after TIA, and risk of
hemorrhage is expected to be lower than after a completed
stroke, so the combination may be particularly eﬀective and
relatively safe in this setting representing a new frontier to be
explored.
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